Stroke Prevention in Atrial Fibrillation: Looking Forward.
Stroke Prevention in Atrial Fibrillation: Looking Forward.
Circulation. 2020 Dec 15;142(24):2371-2388
Authors: Katsanos AH, Kamel H, Healey JS, Hart RG
Abstract
Ischemic strokes related to atrial fibrillation are highly prevalent, presenting with severe neurologic syndromes and associated with high risk of recurrence. Although advances have been made in both primary and secondary stroke prevention for patients with atrial fibrillation, the long-term risks for stroke recurrence and bleeding complications from antithrombotic treatment remain substantial. We summarize the major advances in stroke prevention for patients with atrial fibrillation during the past 30 years and focus on novel diagnostic and treatment approaches currently under investigation in ongoing clinical trials. Non-vitamin K antagonist oral anticoagulants have been proven to be safer and equally effective compared with warfarin in stroke prevention for patients with nonvalvular atrial fibrillation. Non-vitamin K antagonist oral anticoagulants are being investigated for the treatment of patients with atrial fibrillation and rheumatic heart disease, for the treatment of patients with recent embolic stroke of undetermined source and indirect evidence of cardiac embolism, and in the prevention of vascular-mediated cognitive decline in patients with atrial fibrillation. Multiple clinical trials are assessing the optimal timing of non-vitamin K antagonist oral anticoagulant...
Source: Circulation - Category: Cardiology Authors: Katsanos AH, Kamel H, Healey JS, Hart RG Tags: Circulation Source Type: research
More News: Atrial Fibrillation | Bleeding | Brain | Cardiology | Clinical Trials | Colchicine | Colcrys | Coumadin | Heart | Heart Disease | Ischemic Stroke | Neurology | Rheumatology | Stroke | Vitamin K | Vitamins | Warfarin